Browsing Tag
Corcept Therapeutics
3 posts
Ovarian cancer treatment options, survival rates, and the newest FDA approvals in 2026
Ovarian cancer affects 21,000 US women annually. This guide covers symptoms, staging, survival rates, BRCA risk, and the newest FDA-approved treatments through early 2026.
Why did the FDA double down on rejecting Corcept’s flagship drug? Investors rattled
Corcept Therapeutics faces fresh regulatory headwinds as the FDA revises its relacorilant rejection letter, highlighting safety concerns and strategic missteps. Read more.
Corcept Therapeutics submits FDA application for relacorilant to treat Cushing’s syndrome
Corcept Therapeutics Incorporated has taken a significant step in addressing the unmet needs of patients with hypercortisolism, commonly…